Abeona Therapeutics Inc
F:PCJ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Abeona Therapeutics Inc
F:PCJ
|
US |
|
C
|
Charles Schwab Corp
XMUN:SWG
|
US |
|
Gold Fields Ltd
F:EDGA
|
ZA |
|
B
|
Barrick Gold Corp
XMUN:ABR
|
CA |
|
Atlassian Corporation PLC
NASDAQ:TEAM
|
UK |
|
M
|
Marsh & McLennan Companies Inc
SWB:MSN
|
US |
|
Nickel Industries Ltd
F:NM5
|
AU |
|
S
|
Sands China Ltd
XMUN:599A
|
MO |
|
M
|
Murray & Roberts Holdings Ltd
SWB:LDYA
|
ZA |
|
C
|
Clorox Co
XMUN:CXX
|
US |
Wall St Price Targets
PCJ Price Targets Summary
Abeona Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for PCJ is 14.345 EUR with a low forecast of 10.087 EUR and a high forecast of 20.974 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is PCJ's stock price target?
Price Target
14.345
EUR
According to Wall Street analysts, the average 1-year price target for PCJ is 14.345 EUR with a low forecast of 10.087 EUR and a high forecast of 20.974 EUR.
What is the Revenue forecast for Abeona Therapeutics Inc?
Projected CAGR
71%
Over the last 13 years, the compound annual growth rate for Revenue has been 2%. The projected CAGR for the next 8 years is 71%.
What is the Gross Profit forecast for Abeona Therapeutics Inc?
Projected CAGR
280%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 0%. The projected CAGR for the next 3 years is 280%.
What is the Pre-Tax Income forecast for Abeona Therapeutics Inc?
Projected CAGR
-22%
The compound annual growth rate for Pre-Tax Income over the next 3 years is -22%.
What is the Net Income forecast for Abeona Therapeutics Inc?
Projected CAGR
18%
The compound annual growth rate for Net Income over the next 8 years is 18%.
